Brainscape's Knowledge GenomeTM


Top Flashcards (Certified)
All Flashcards

Pharm Drug Table > Drug Table - Misc Agents > Flashcards

Drug Table - Misc Agents Flashcards

(76 cards)

Start Studying
1
Q

Imatinib (Gleevac) Class

A

Tyrosine Kinase

inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Imatinib (Gleevac) Mechanism

A

Inhibits Abl kinase by binding where ATP
should go; also inhibits PDGFR and c-kit;
metabolized by cytochrome P450

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Imatinib (Gleevac) Therapeutics

A 
First line therapy for CML; also,
gastrointestinal tumor (GIST)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Imatinib (Gleevac) Imp Side effects

A

Nausea and vomiting, fluid
retention, muscle cramps,
arthralgia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Imatinib (Gleevac) Other side effects

A

Myelosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Imatinib (Gleevac) Misc

A

Oral (1/day)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Gefitinib (Iressa) Class

A

Tyrosine Kinase

inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Gefitinib (Iressa) Mechanism

A

Inhibit epidermal growth factor receptor

(EGFR) tyrosine kinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Gefitinib (Iressa) Therapeutics

A

Non-small lung cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Erlotinib (Tarceva) Class

A

Tyrosine Kinase

inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Erlotinib (Tarceva) Mechanism

A

Inhibit epidermal growth factor receptor

(EGFR) tyrosine kinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Erlotinib (Tarceva) Therapeutics

A

Non-small lung cancer

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Nilotinib (Tasigna) class

A

Tyrosine Kinase

inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Nilotinib (Tasigna) Mechanism

A

Inhibits Abl kinase

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Nilotinib (Tasigna) Therapeutics

A

Imatinib-resistant CML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Nilotinib (Tasigna) Imp side effects

A

Myelosuppression

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Nilotinib (Tasigna) other side effects

A

QT prolongation, hepatotoxicity,

electrolyte abnormalities

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Nilotinib (Tasigna) misc

A

Oral (2/day)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Dasatinib (Sprycel) class

A

Tyrosine Kinase

inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Dasatinib (Sprycel) mechanism

A

Inhibits Abl & Src kinases

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

Dasatinib (Sprycel) therapeutics

A

Imatinib-resistant CML

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Dasatinib (Sprycel) Imp side effects

A

Myelosuppression, bleeding, fluid
retention, pulmonary arterial
hypertension

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Dasatinib (Sprycel) other side effects

A

Diarrhea, nausea and vomiting,

weakness, infections

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

Dasatinib (Sprycel) misc

A

Oral (1/day)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Rituximab (Rituxan) class
Monoclonal | antibody
26
Rituximab (Rituxan) mechanism
CD20 B-cell antibody that can directly activate apoptosis, activate complement, or activate cell-mediated cytotoxicity (e.g., T cells, NK cells)
27
Rituximab (Rituxan) therapeutics
Non-Hodgkin's lymphomas
28
Rituximab (Rituxan) imp side effects
``` Infusion reactions, tumor lysis syndrome (TLS), severe mucocutaneous reactions, progressive multifocal leukoencephalopathy (PML) ```
29
Rituximab (Rituxan) other side effects
Skin reactions, irregular | heartbeat, muscle or joint pain
30
Rituximab (Rituxan) misc
Patients need careful monitoring
31
Trastuzumab (Herceptin) class
Monoclonal | antibody
32
Trastuzumab (Herceptin) mechanism
Unknown HER2/neu (ErbB2) receptor antibody mechanism (enhanced receptor endocytosis or blocking homo- or heterodimerization)
33
Trastuzumab (Herceptin) therapeutics
HER2/neu-overexpressing metastatic | breast cancer
34
Trastuzumab (Herceptin) Imp side effects
Hypersentivity reaction; ventricular | dysfunction
35
Trastuzumab (Herceptin) misc
Usually combined with taxanes; | enhances doxorubicin cardiotoxicity
36
Cetuximab (Erbitux) class
Monoclonal | antibody
37
Cetuximab (Erbitux) mechanism
EGFR1 (ErbB1)
38
Cetuximab (Erbitux) therapeutics
EGFR-positive metastatic colorectal | cancer
39
Cetuximab (Erbitux) imp side effects
Allergic reactions, sudden cardiac death, dermatologic problems, infections, renal failure, electrolyte abnormalities
40
Cetuximab (Erbitux) other side effects
Asthenia/malaise, fever, nausea, constipation, interstitial pneumonitis
41
Cetuximab (Erbitux) misc
Clinical trials, probably combine with | cisplatin
42
Cetuximab (Erbitux) class
Monoclonal | antibody
43
Cetuximab (Erbitux) mechanism
EGFR1 (ErbB1)
44
Cetuximab (Erbitux) therapeutics
EGFR-positive metastatic colorectal | cancer
45
Cetuximab (Erbitux) imp side effects
Allergic reactions, sudden cardiac death, dermatologic problems, infections, renal failure, electrolyte abnormalities
46
Cetuximab (Erbitux) other side effects
Asthenia/malaise, fever, nausea, constipation, interstitial pneumonitis
47
Cetuximab (Erbitux) misc
Clinical trials, probably combine with | cisplatin
48
Ipilimumab (Yervoy) class
Human monoclonal antibody
49
Ipilimumab (Yervoy) mechanism
Cytotoxic T-Lymphocyte Antigen 4 inhibitor; | stimulates immune system
50
Ipilimumab (Yervoy) therapeutics
Melanoma
51
Vemurafenib (Zelboraf) class
Serine/threonine | kinase inhibitor
52
Vemurafenib (Zelboraf) mechanism
Inhibits oncogenic BRAF kinase
53
Vemurafenib (Zelboraf) therapeutics
Unresectable Stage III and IV or metastatic melanomas w/BRAF mutations
54
Vemurafenib (Zelboraf) imp side effects
Arthralgia, fatigue, photosensitivity, nausea, alopecia, diarrhea, QT prolongation
55
Vemurafenib (Zelboraf) other side effects
Cutaneous squamous cell carcinoma, keratoacanthoma, new primary cutaneous melanoma
56
Vemurafenib (Zelboraf) misc
Superior to dacarbazine in Phase III | trials
57
Dabrafenib (Tafinlar) class
Serine/threonine | kinase inhibitor
58
Dabrafenib (Tafinlar) mechanism
Inhibits oncogenic BRAF kinase
59
Dabrafenib (Tafinlar) therapeutics
Unresectable Stage III and IV or metastatic melanomas w/BRAF mutations
60
Dabrafenib (Tafinlar) imp side effects
Serious febrile drug reactions, uveitis and iritis, hyperglycemia, hyperkeratosis
61
Dabrafenib (Tafinlar) other side effects
Higher risk of developing: Serious febrile drug reactions, uveitis and iritis, hyperglycemia, hyperkeratosis
62
Dabrafenib (Tafinlar) misc
May cause male infertility
63
Trametinib (Mekinist) mechanism
Inhibits MEK
64
Trametinib (Mekinist) therapeutics
Unresectable Stage III and IV or metastatic melanomas w/BRAF mutations
65
Trametinib (Mekinist) imp side effects
Cardiomyopathy, retinal disorders, interstitial lung disease, serious skin toxicities
66
Trametinib (Mekinist) other side effects
Rash, diarrhea, stomatitis, | hypertension, pruritis
67
Trametinib (Mekinist) misc
May cause female infertility
68
Hydroxyurea (Hydrea) mechanism
Inhibits ribonucleoside diphosphate | reductase
69
Hydroxyurea (Hydrea) therapeutics
CML (replaced by Imatinib), polycythemia vera, essential thrombocythemia; treatment for sickle cell disease (increases Hb-F)
70
Retinoids Mechanism
ATRA induces terminal differentiation in malignant immature promyelocytes, which subsequently apoptose
71
Retinoids Therapeutics
APL
72
Retinoids imp side effects
"Leukocyte Activation Syndrome" (LAS), an increase in WBCs (fever, weight gain, respiratory distress, serosal effusion, renal failure)
73
Retinoids misc
Combined w/anthracyclines; | corticosteroids used to block "LAS"
74
Arsenic Trioxide (Trisenox) Therapeutics
Relapsed APL
75
Thalidomide (Thalomid) Therapeutics
Multiple myeloma and myelodysplastic | syndromes
76
Interferons
Hairy-cell leukemia, CML, and AIDSrelated | Kaposi's sarcoma

Pharm Drug Table (11 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions